Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review

Plus Therapeutics (NASDAQ:PSTV) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Plus Therapeutics and Stevanato Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	0	0	2	0	3.00
Stevanato Group	0	1	5	0	2.83

Plus Therapeutics currently has a consensus target price of $13.50, indicating a potential upside of 988.71%. Given Plus Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Plus Therapeutics is more favorable than Stevanato Group.

Profitability

This table compares Plus Therapeutics and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-225.07%	N/A	-154.56%
Stevanato Group	10.47%	9.86%	5.79%

Valuation and Earnings

This table compares Plus Therapeutics and Stevanato Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$4.91 million	1.49	-$13.32 million	($2.53)	-0.49
Stevanato Group	$1.09 billion	6.49	$157.62 million	€0.47 ($0.48)	51.15

Stevanato Group has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Plus Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

3.3% of Plus Therapeutics shares are held by institutional investors. 5.5% of Plus Therapeutics shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Stevanato Group beats Plus Therapeutics on 9 of the 14 factors compared between the two stocks.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.